RESEARCH MONOGRAPH · KDC-MN-129

Thymogen

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

50/100

A two-residue dipeptide from the Khavinson program with reasonable immune modulation signal but extreme reductionism

Thymogen is Glu-Trp. Two amino acids. That's the whole molecule. It came out of the same St. Petersburg bioregulator program that gave us Thymalin and a bunch of other ultra-short peptides, and the design rationale was to take what the Khavinson group thought were the minimum bioactive elements of larger thymic peptides and reduce them to the simplest possible sequences.

Whether you find this plausible depends on how much you buy the bioregulator framework. The published Russian work shows Thymogen having effects on T-cell function, neutrophil activity, and various immune readouts in animal models and small clinical series, mostly in respiratory and infectious indications. The dipeptide is administered intranasally or by injection in those papers.

What we like: it's chemically trivial to characterize. Glu-Trp is easy to verify. The intranasal administration is operationally interesting if you're studying peptides that need to cross the cribriform plate. And there's a coherent body of literature, even if most of it is in Russian.

What we dont like: a dipeptide having that much specific biological activity is a high prior bar. Dipeptides are essentially everywhere in protein hydrolysates; the case for Glu-Trp having a unique signaling role needs more rigorous orthogonal validation than the literature provides. Western pharmacology hasn't replicated the core findings independently in any depth, and the Khavinson framework has a track record of producing claims that look thin under outside scrutiny.

Mechanism is essentially a black box. There's no defined receptor, no mapped signaling pathway, just observational outcomes. The Khavinson program treats this as okay because they argue the dipeptides interact with DNA directly as epigenetic regulators, but thats a controversial claim that doesnt have strong independent support.

Sourcing: synthetic dipeptide, extremely cheap to make, easy to characterize. So the technical reliability is fine. The question is just whether the molecule does what the literature claims.

Honestly, this is hedge territory. We dont have strong opinions because the foundational evidence isnt strong enough to form strong opinions on. If you're investigating the bioregulator framework, Thymogen is part of the picture. If you're not, the case for prioritizing it is thin.

Evidence: 35
Mechanism: 30
Reliability: 45
Safety: 75
Sourcing: 75
Value: 55
Signal: 45
Staying power: 40

Plain-language summary Intrigue 45 / 100

Thymogen is a synthetic dipeptide (Glu-Trp) immunomodulator developed in Russia, derived from research on thymic hormones. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Synthetic dipeptide immunomodulator

A synthetic dipeptide (Glu-Trp) developed in Russia as an immunomodulator for infectious and post-surgical immune support.

Abstract

Thymogen is the dipeptide L-glutamyl-L-tryptophan, developed in Russia at the Institute of Bioregulation and Gerontology. The compound was identified through fractionation of thymalin (bovine thymus extract) as one of the active components. Thymogen is approved in Russia and several former Soviet states for infectious diseases, post-surgical immune support, and hematopoietic recovery after chemotherapy. Mechanism includes modest T-cell maturation effects and cytokine modulation. Administered intranasally or intramuscularly. Reported research dose ranges in the literature are around 100 micrograms over short courses.

Mechanism of action

Glu-Trp dipeptide; T-cell maturation and cytokine modulation.

Reported research dose ranges

Reported research dose ranges in the literature: around 100 micrograms (intranasal or intramuscular) over short courses.

References

Khavinson VK. Synthetic peptide bioregulators. Russian Academy of Medical Sciences.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-129

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Thymogen

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs